Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

Inclusion Criteria: Subjects must meet all of the following inclusion criteria: * Subject able to provide written informed consent. * Male or non-pregnant females between the ages of 18 and 49 years, inclusive. * Women of childbearing potential must be practicing abstinence or using an acceptable method of birth control for at least 30 days prior to enrollment through day 45 after receipt of the challenge virus. Male subjects must agree not to father a child prior to day 45 after receipt of the challenge virus. * A woman is considered of childbearing potential unless post-menopausal (absence of menses for \>/= 1 year) or surgically sterilized (tubal ligation, bilateral oophorectomy or hysterectomy). * Acceptable contraception methods for women include but are not limited to: sexual abstinence from intercourse with men, monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject enrolling in the study, barrier methods such as condoms or diaphragms with spermicide or foam, effective devices (IUDs, NuvaRing®) or licensed hormonal products such as implants, injectables or oral contraceptives. * For women of childbearing potential, must have a negative serum or urine pregnancy test at screening and negative urine or serum pregnancy test within 24 hours prior to challenge. * Are in good general health, as determined by the study investigator within 60 days of challenge. * Demonstrate knowledge and comprehension of the…